India, Sept. 9 -- Tyra Biosciences Inc. (TYRA) shares are currently trading at $20.77, down $5.96, or 22.27 percent on Wednesday, despite the company reporting encouraging initial results from its Phase 2 SURF302 study of oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer.
Tyra closed the previous session at $26.73 and opened at $18.94 on the Nasdaq. The stock has traded between $18.76 and $21.37, with volume at 2.80 million shares, compared with average volume of 740,662. Its 52-week range is $11.70 to $40.65.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
At the 60 mg once-daily dose, patients with a single marker lesion achieved a 100 pe...